Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Thyroid cancer: a review
Importance Approximately 43 720 new cases of thyroid carcinoma are expected to be
diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review …
diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review …
Thyroid cancer
The past 5–10 years have brought in a new era in the care of patients with thyroid cancer,
with the introduction of transformative diagnostic and management options. Several …
with the introduction of transformative diagnostic and management options. Several …
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2 …
Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …
Leveraging large language models for decision support in personalized oncology
Importance Clinical interpretation of complex biomarkers for precision oncology currently
requires manual investigations of previous studies and databases. Conversational large …
requires manual investigations of previous studies and databases. Conversational large …
Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology
Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Overview of the 2022 WHO classification of neuroendocrine neoplasms
In this review, we detail the changes and the relevant features that are applied to
neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and …
neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and …
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …